Stockhead’s Sarah Hughan sits down with AdAlta (ASX:1AD) CEO and managing director Tim Oldham to get the short end of the long story on the company’s latest news.

The clinical stage biotechnology company has released its quarterly activities report for the quarter ended June 30, 2024.

The report highlights a substantially strengthened cash position and advances in two business units.

Tune in to hear Ad Alta’s Tim Oldham on the key financials, partnership discussions, and more.

 

This video was developed in collaboration with AdAlta, a Stockhead advertiser at the time of publishing.

The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.

Read MoreAusbiotech

Featured Companies

You might be interested in